Anti-androgen shows benefit as adjuvant PCa therapy

May 1, 2004

Vienna, Austria--The first analysis of the Early Prostate Cancer program-presented3 years ago at the European Association of Urology annual congress-revealedthat the anti-androgen bicalutamide (Casodex), 150 mg, cuts prostate cancerprogression risk almost in half in patients with localized or locally advanceddisease. A second analysis, presented at this year's meeting, confirmedthat the earlier finding holds true whether patients are treated with radicalprostatectomy, radiotherapy, or watchful waiting.